Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.13+9.0% vs -$0.14 | — vs — |
Q2 2026 May 8, 2026 | -$0.17-13.3% vs -$0.15 | — vs — |
Q1 2026 Feb 27, 2026 | -$0.42-10.5% vs -$0.38 | — vs — |
Q4 2025 Nov 7, 2025 | -$0.41-10.8% vs -$0.37 | — vs — |
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
BlackRock Inc. bought a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,399,530 shares of the company's stock, valued at approximately $15,317,000. BlackRock Inc. owned 5.50% of ALX Oncology
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.
5AM Venture Management LLC acquired a new position in shares of ALX Oncology Holdings Inc. (NASDAQ: ALXO) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,057,325 shares of the company's stock, valued at approximately $6,328,663,000. ALX Oncology makes up
Benchmark ALXO against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ALX Oncology Holdings Inc. (ALXO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.22 | $164.17M | -0.64 | — | — | -145.7% | — | |
| $2.32 | $270.42M | -2.02 | -51.24% | -1941.09% | -65.08% | — | |
| $33.62 | $6.94B | -12.14 | — | -7585.86% | -69.59% | — | |
| $24.44 | $3.07B | -7.43 | -4.26% | -386.32% | -87.98% | — | |
| $8.36 | $348.13M | -2458.82 | 10.37% | 69.76% | — | — | |
| $43.58 | $1.44B | -4.48 | -43.89% | -287.84% | -37.99% | — |
ALX Oncology Holdings Inc. (ALXO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ALX Oncology Holdings Inc. (ALXO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 30, 2026·SEC
Jun 26, 2026·SEC
Get notified when ALXO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALX Oncology Holdings Inc. (ALXO) stock FAQ — growth, dividends, profitability & financials explained
ALX Oncology Holdings Inc. (ALXO) reported a net loss of $80.9M for fiscal year 2025.
ALX Oncology Holdings Inc. (ALXO) has a return on equity (ROE) of -145.7%. Negative ROE indicates the company is unprofitable.
ALX Oncology Holdings Inc. (ALXO) had negative free cash flow of $89.6M in fiscal year 2025, likely due to heavy capital investments.
